Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. weekly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E8.29 EPS (ttm)8.79 Insider Own0.20% Shs Outstand1.31B Perf Week1.41%
Market Cap95.06B Forward P/E10.60 EPS next Y6.87 Insider Trans-26.72% Shs Float1.30B Perf Month-9.09%
Income11.60B PEG- EPS next Q1.69 Inst Own79.60% Short Float1.51% Perf Quarter-1.62%
Sales27.48B P/S3.46 EPS this Y-16.50% Inst Trans2.70% Short Ratio2.05 Perf Half Y12.79%
Book/sh19.02 P/B3.83 EPS next Y-20.99% ROA19.40% Target Price84.90 Perf Year-2.20%
Cash/sh21.75 P/C3.35 EPS next 5Y-12.39% ROE53.40% 52W Range63.76 - 86.27 Perf YTD1.69%
Dividend2.08 P/FCF10.45 EPS past 5Y41.20% ROI31.00% 52W High-15.59% Beta1.17
Dividend %2.86% Quick Ratio3.60 Sales past 5Y29.40% Gross Margin84.80% 52W Low14.21% ATR1.44
Employees9000 Current Ratio3.70 Sales Q/Q-13.20% Oper. Margin57.80% RSI (14)36.32 Volatility1.30% 2.03%
OptionableYes Debt/Eq1.18 EPS Q/Q-17.10% Profit Margin42.20% Rel Volume0.46 Prev Close72.51
ShortableYes LT Debt/Eq1.11 EarningsOct 26 AMC Payout22.90% Avg Volume9.55M Price72.82
Recom2.50 SMA20-1.51% SMA50-7.64% SMA2001.04% Volume4,364,359 Change0.43%
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Nov-23-17 10:41AM  Can Gilead Sciences Incs (GILD) ROE Continue To Surpass The Industry Average? Simply Wall St.
08:04AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-22-17 10:29AM  Gilead: The Leader of the Packor Just Another Follower? Barrons.com
09:28AM  J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen Zacks
09:00AM  Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6 Business Wire
Nov-21-17 12:35PM  The 1 Thing Missing From Gilead Sciences' 2018 Priority List Motley Fool
11:26AM  This is what a Trump-stacked Federal Reserve will look like Yahoo Finance Video
11:26AM  Bitcoin barely bats an eye after $31 million cryptocurrency heist Yahoo Finance Video
10:31AM  How Mercks Zepatier and Isentress Are Positioned Market Realist
Nov-20-17 11:05AM  Here's what will be moving stocks this week Yahoo Finance Video
11:05AM  Bitcoin's next stop is $9,000or $7,000 Yahoo Finance Video
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-18-17 09:37AM  Better Buy: Biogen Inc. vs. Gilead Sciences Motley Fool
Nov-17-17 07:09AM  Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3 Zacks
Nov-16-17 05:43PM  Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms Investor's Business Daily
Nov-15-17 08:17PM  3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock Motley Fool
08:57AM  Trade of the Day: Gilead Sciences, Inc. (GILD) InvestorPlace
08:10AM  Todays Research Reports on Trending Tickers: Gilead Sciences and Geron Corporation ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-14-17 03:03PM  7 Life Science Stocks to Buy Today InvestorPlace
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-13-17 09:28PM  What Investors Need to Know About Investing in Low PE Stocks Motley Fool
05:18PM  Biotech ETFs: What Lies Ahead? Zacks
03:43PM  Gilead: Falling Sales+Higher Spending=Lower Profits Barrons.com
10:15AM  As Gilead's Outlook Dims, Argus Downgrades Benzinga
Nov-12-17 08:00AM  3 Top Biotech Stocks for 2018 Motley Fool
Nov-10-17 10:40AM  Short Sellers Grow More Selective on Major Biotechs 24/7 Wall St.
Nov-09-17 02:53PM  Biotech Celgene Could Rebound By More Than 15% Investopedia
08:53AM  You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018 Motley Fool
02:41AM  Edited Transcript of GILD earnings conference call or presentation 26-Oct-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 07:04PM  Cramer's lightning round: Step aside, Exxon. Cimarex's mo... CNBC Videos
01:14PM  6 Reasons Gilead Didn't Overpay for Kite Barrons.com
01:05PM  How Gilead Sciences Has Maintained Its Dividend Trajectory Market Realist
08:00AM  Today's Research Reports on Trending Tickers: Exact Sciences and Gilead Sciences ACCESSWIRE
Nov-06-17 03:25PM  Top 5 Biotech Stocks for 2017 Investopedia
03:04PM  Bluebird: Can It Keep Singing? Barrons.com
12:43PM  Glaxo vs Gilead: Put 'Em Up? Barrons.com
Nov-03-17 01:52PM  Nine years of outsized stimulus is finally taking hold in the US economy: NYSE trader Yahoo Finance Video
Nov-02-17 03:13PM  What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October? Motley Fool
02:49PM  Why Juno Therapeutics Shares Are Going Up 21.2% Today Motley Fool
10:38AM  GSK and Gilead go head to head as HIV drugs enter new phase Reuters
04:45AM  Sharp Drop Celgene Corporation Stock May Have Just Created an Entry Point InvestorPlace
12:49AM  [$$] Risk, Reward and the Pricing of New Drugs The Wall Street Journal
Nov-01-17 05:48PM  [$$] Risk, Reward and the Pricing of New Drugs The Wall Street Journal
09:46AM  Can Juno Therapeutics Outmaneuver Its CAR-T Competitors? Motley Fool
09:02AM  How Gileads Drugs Performed in 3Q17 Market Realist
07:32AM  Gileads Hepatitis C Drugs: Performances in 3Q17 Market Realist
Oct-31-17 03:00PM  Gileads HIV Drugs Atripla, Truvada, and Stribild in 3Q17 Market Realist
02:29PM  Ionis Down Big on Analyst Miss Motley Fool
01:30PM  Gileads TAF-Containing HIV Products Saw Solid Growth in 3Q17 Market Realist
11:56AM  How Gilead Sciences Performed in 3Q17 Market Realist
10:57AM  The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens Zacks
08:26AM  MSF charity secures generic hepatitis C drugs for $1.40 a day Reuters
07:30AM  Featured Company News - Celgene Presents Detailed Results from First Phase-III Trial of Oral Ozanimod (SUNBEAM(TM)) ACCESSWIRE
06:00AM  3 Stocks Top Managers Have Been Buying Morningstar
Oct-30-17 03:13PM  How Celgene, Gilead's Pricing Woes Continue To Haunt Biotech Stocks Investor's Business Daily
01:55PM  Top Research Reports for JPMorgan Chase, Gilead & ConocoPhillips Zacks
10:41AM  What's in the Cards for PFE, INCY and ACOR in Q3 Earnings? Zacks
10:07AM  Company News For Oct 30, 2017 Zacks
Oct-29-17 03:04PM  3 ETFs to Watch on Biotech Earnings Zacks
10:30AM  Gilead Sciences, Inc. (GILD) Stock Isnt Worth It Here InvestorPlace
09:07AM  5 Things You Need to Know From Gilead Sciences' Q3 Update Motley Fool
Oct-27-17 02:23PM  Biotech stocks are getting slammed by earnings and Trump's Tweets: NYSE trader Yahoo Finance Video
02:23PM  Gilead Sciences, Inc. Stock Is a Buy When It Seems Like It Shouldnt Be InvestorPlace
10:38AM  Nasdaq Having Best Day in 2 Months as Amazon and Alphabet Drive Tech Stock Gains TheStreet.com
09:58AM  Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat Zacks
09:21AM  The Biotech Blues: Gilead's Earnings Another Sour Note in a Week Full of Them Barrons.com
09:03AM  Tech Trio Drives Gains in Stock Futures While U.S. GDP Rises at Healthy Pace TheStreet.com
08:20AM  Today's Research Reports on Stocks to Watch: Gilead Sciences and Celgene Corporation ACCESSWIRE
07:00AM  3 Stocks to Watch on Friday: Baidu Inc (ADR) (BIDU), Gilead Sciences, Inc. (GILD) and Mattel, Inc. (MAT) InvestorPlace
Oct-26-17 07:32PM  Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter Motley Fool
06:47PM  [$$] Gilead Looks Away From Hepatitis C Treatments for Growth The Wall Street Journal
05:58PM  Gilead (GILD) Q3 Earnings and Revenues Sink Zacks
05:47PM  Gilead Sciences, Inc.s (GILD) Q3:17 Earnings Send Shares Lower SmarterAnalyst
05:30PM  Gilead profit beats estimates, but shares drop after hours Reuters
05:03PM  Gilead Tops Sales, Profit Views But Misses On Hep C; Shares Fall Investor's Business Daily
04:40PM  Gilead 3rd-quarter profit falls, but beats Wall Street estimates Reuters
04:33PM  Gilead beats Street 3Q forecasts Associated Press
04:14PM  Gilead beats the Street CNBC Videos
04:13PM  Gilead shares higher after earnings, revenue beat MarketWatch
04:02PM  Gilead Sciences Announces Fourth Quarter 2017 Dividend Business Wire
04:01PM  Gilead Sciences Announces Third Quarter 2017 Financial Results Business Wire
01:13PM  Cambrex Corporation (CBM): 33% Downside Risk According to Lakewood Capital Investor Letter Insider Monkey
11:13AM  Gilead Sciences, Inc. Stock Looks Good Regardless of Quarterly Earnings Report InvestorPlace
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Oct-25-17 11:48AM  Gilead Sciences: A Nash Smashup in Pharma? Barrons.com
09:49AM  Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More Zacks
08:30AM  Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season? Zacks
08:01AM  Gileads Patents on Hepatitis C Drug Challenged by Consumer Group Bloomberg
Oct-24-17 04:01PM  Gilead Sciences to Present at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7 Business Wire
03:24PM  3 Healthcare Value Stocks Motley Fool
10:33AM  Why Biogen May Sink Biotech Sector As Earnings Beat Investopedia
09:39AM  Healthcare ETFs Set to Soar as Q3 Earnings Unfold Zacks
08:52AM  Gilead Sciences says its NASH therapy had positive results in mid-stage trial MarketWatch
08:36AM  Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) Business Wire
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
08:00AM  Better Buy: Gilead Sciences, Inc. vs. Amgen Motley Fool
07:15AM  IBD's No. 1 Group Under Pressure; These 6 Key Earnings Loom; S&P 500 Futures Investor's Business Daily
Oct-23-17 04:08PM  What Analysts Project for Eli Lilly in 3Q17 Market Realist
02:30PM  How Earnings Will Fuel Biotech's Bull Run: BMO Capital Investopedia
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM